Trial Profile
An open-label study to assess the safety, tolerability and multiple-dose phamacokinetics of AA4500 0.58 mg in subjects with Dupuytren's contractures
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Collagenase clostridium histolyticum (Primary)
- Indications Dupuytren's contracture
- Focus Adverse reactions; Registrational
- Sponsors Auxilium Pharmaceuticals
- 06 Jun 2014 New trial record
- 08 May 2014 According to a Biospecifics Technologies Corporation media release, the supplement biologics license application (sBLA) for potential label expansion of Xiaflex is under FDA review with a PDUFA date of October 20, 2014.